How should tranexamic acid be added to continuous bladder irrigation (CBI) solution for management of hematuria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tranexamic Acid Administration in Continuous Bladder Irrigation for Hematuria

Add 1000 mg of tranexamic acid directly into the bladder via the Foley catheter, allow it to dwell for 15 minutes with the catheter clamped, then declamp and initiate continuous bladder irrigation. This intravesical approach has demonstrated significant reductions in bleeding duration, irrigation requirements, and emergency department length of stay 1.

Administration Protocol

Intravesical (Direct Bladder) Administration

  • Dose: 1000 mg tranexamic acid
  • Route: Inject through the 3-way Foley catheter directly into the bladder
  • Dwell time: Clamp catheter for 15 minutes after injection
  • Then: Declamp and begin standard CBI with normal saline

This method resulted in:

  • Median ED length of stay reduced from 411 to 274 minutes (p < 0.001)
  • Foley catheter duration decreased from 308 to 145 minutes (p < 0.001)
  • Revisit rates dropped from 12.3% to 2.3% (p = 0.031) 1

Alternative: TXA in Irrigation Fluid

For surgical cases (particularly percutaneous nephrolithotomy), 0.1% tranexamic acid concentration in the irrigant solution is effective:

  • Significantly reduces perioperative blood loss (154.55 vs 212.61 mL, p < 0.0001)
  • Decreases transfusion requirements (5% vs 12.5%, p = 0.012)
  • Lowers complication rates (19% vs 28%, p = 0.044) 2

Pharmacologic Considerations from FDA Labeling

Standard IV dosing (for reference, though intravesical is preferred for CBI):

  • 1 g IV over 10 minutes (at 1 mL/min)
  • Second dose of 1 g if bleeding continues after 30 minutes 3
  • Terminal half-life: approximately 11 hours
  • 95% excreted unchanged in urine 3

Critical Safety Parameters

Renal Function Adjustment Required

Dose reduction is mandatory in renal impairment since TXA is eliminated via glomerular filtration:

  • Serum creatinine 1.4-2.8 mg/dL: 51% urinary excretion at 24 hours
  • Serum creatinine 2.8-5.7 mg/dL: 39% urinary excretion
  • Serum creatinine >5.7 mg/dL: 19% urinary excretion 3

Contraindications and Warnings

  • Do NOT use in patients on all-trans retinoic acid (tretinoin) - 3 of 4 patients died from thrombotic complications in one series 3
  • Monitor for thromboembolic events, though none were reported in recent urologic series 4
  • No evidence of increased renal failure risk from urinary clots in systematic review of 342 patients 5

Evidence Quality Assessment

The intravesical approach 1 represents the most practical and effective method for emergency department hematuria management, with a 2023 publication date making it the most current evidence. The before-and-after study design (N=159 patients) showed consistent benefits across multiple clinically relevant endpoints.

The 0.1% irrigation concentration 2 is better suited for intraoperative use during urologic procedures (2017 RCT, N=400), where it can be continuously administered throughout the case.

Common Pitfalls to Avoid

  1. Don't add TXA to CBI bags for continuous infusion in non-surgical hematuria - the single intravesical bolus with dwell time is more effective and evidence-based
  2. Don't skip the 15-minute dwell time - this allows local tissue penetration and antifibrinolytic effect
  3. Don't forget renal dose adjustment - standard dosing in renal impairment risks accumulation
  4. Don't use in patients with history of thromboembolic disease without careful risk-benefit analysis

The mechanism involves saturating plasminogen's high-affinity lysine binding sites (Kd = 1.1 µmol/L), preventing fibrin matrix dissolution while preserving hemostatic clot structure 3.

Related Questions

What is the appropriate dosing, route, duration, and monitoring for tranexamic acid in the management of non‑life‑threatening hematuria?
How should I evaluate and manage a patient presenting with hematuria and flushing, including appropriate investigations, treatment (e.g., tranexamic acid), and monitoring?
Can tranexamic acid be used to treat gross hematuria?
Can tranexamic acid be administered for urethral bleeding after clean intermittent catheterization?
Can a urinalysis be obtained while continuous bladder irrigation (CBI) is in progress?
Can ursodeoxycholic acid be administered to a patient with acute kidney injury or chronic kidney disease who has a mildly elevated total bilirubin (~2 mg/dL)?
Can Suboxone (buprenorphine/naloxone) cause a false‑positive urine drug screen for oxycodone?
When should lisinopril be used instead of olmesartan for hypertension, and what are the recommended dosing and monitoring considerations?
What is the appropriate management for a patient with a 1 mm × 1 mm laterally oriented outpouching in the cavernous segment of the right internal carotid artery (possible aneurysm), a hypoplastic right vertebral artery that supplies most flow to the posterior inferior cerebellar artery (PICA) with a diminutive mid‑to‑distal V4 segment, patent proximal intracranial arteries, and a hypoplastic anterior communicating artery?
How should I evaluate and manage wide systolic blood pressure fluctuations (approximately 220 mmHg to 120 mmHg) in a mechanically ventilated adult patient?
What is the recommended treatment plan for a patient with subscapularis tendinitis/tendinosis with a subtle intratendinous delaminated partial‑thickness tear, infraspinatus tendinitis/tendinosis with an intratendinous delaminated partial‑thickness tear, a superior labrum anterior to posterior (SLAP) labral tear, moderate acromioclavicular (AC) joint degenerative joint disease, and a slight joint effusion with subdeltoid and subacromial bursitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.